Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
  • C07D213/32—Sulfur atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D213/58—Amidines

Definitions

• This invention relates to certain pyridine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as histamine H 2 -antagonists.
• a histamine a physiologically active compound endogenous in mammals, exerts its action by interacting with certain sites called receptors.
• receptors One type of receptor is known as a histamine H 1 -receptor (Ash and Schild, Brit. J. Pharmac. Chemother. 27 427(1966)) and the actions of histamine mediated through these receptors are blocked by drugs commonly called “antihistamines" (histamine H 1 -antagonists) a common example of which is mepyramine.
• a second type of histamine receptor is known as the H 2 -receptor (Black et al. Nature 1972, 236, 385). These receptors are not blocked by mepyramine but are blocked by burimamide. Compounds which block these histamine H 2 -receptors are called histamine H 2 -antagonists.
• Histamine H 2 -antagonists are useful in treating disease conditions caused by the biological effects of histamine mediated through H 2 -receptors, for example, as inhibitors of gastric acid secretion, in the treatment of inflammation mediated through histamine H 2 -receptors and as agents which act on the cardiovascular system, for example, as inhibitors of effects of histamine on blood pressure mediated through histamine H 2 -receptors.
• Cimetidine is an example of a histamine H 2 -antagonist. Cimetidine has been shown to be useful in the treatment of duodenal, gastric, recurrent and stomal ulceration, and reflux oesophagitis and in the management of patients who are at high risk from haemorrhage of the upper gastrointestinal tract.
• histamine H 1 - and H 2 -receptors In some physiological conditions the biological actions of histamine are mediated through both histamine H 1 - and H 2 -receptors and blockade of both types of receptors is useful. These conditions include inflammation mediated by histamine, for example skin inflammation, and those hypersensitivity responses due to the action of histamine at H 1 - and H 2 -receptors, for example allergies.
• R 3 is C 1-4 alkylene
• R 4 is hydrogen, C 1-6 alkyl, hydroxy-C 2-4 alkyl; optionally substituted phenyl or phenyl (C 1-6 alkyl) (the substituents being one or more C 1-6 alkyl, or C 1-6 alkoxy groups or halogen atoms);
• R 5 and R 6 are the same or different and are hydrogen, C 1-6 alkyl, hydroxy C 2-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, optionally substituted phenyl or phenyl (C 1-6 alkyl), (the substituents being one or more C 1-6 alkyl or C 1-6 alkoxy groups or halogen atoms or a methylenedioxo group), or optionally substituted furanyl- or thienyl- or pyridyl(C 1-6 alkyl) (the substituents being one or more C 1-6 alkyl or C 1-6 alkoxy groups); or taken together represent a C 4-6 alkylene group, or taken together represent a group of formula (2): ##STR2## where R 7 is phenyl or pyridyl and R 8 is hydrogen or C 1-6 alkyl.
• C 1-6 alkyl groups which R 1 and R 2 represent are methyl, ethyl, n-propyl and iso-propyl.
• R 1 and R 2 can be the same C 1-6 alkyl group and in particular they are methyl.
• alkylene groups which R 3 represents are methylene, ethane-1,2-diyl and propane-1,3-diyl.
• R 3 is methylene.
• the group R 1 R 2 NR 3 is dimethylaminomethyl, preferably it is 1-piperidinomethyl.
• C 1-6 alkyl groups for R 4 are methyl, ethyl and n-propyl (particularly methyl).
• C 1-6 alkoxy-C 1-6 alkyl groups for R 4 are methoxyethyl, ethoxymethyl, ethoxypropyl, and propoxymethyl.
• C 3-6 alkenyl groups for R 4 are 2-propenyl and 2-butenyl.
• hydroxy-C 2-4 alkyl groups for R 4 are 2-hydroxyethyl and 3-hydroxypropyl (particularly 2-hydroxyethyl).
• substituted phenyl groups and the substituted phenyl moiety of the phenyl(C 1-6 alkyl) groups for R 4 are 3-methylphenyl, 3-methoxyphenyl, 3,4-dimethoxyphenyl and 3-chlorophenyl.
• Examples of C 1-6 alkyl groups for R 5 and R 6 are methyl, ethyl and n-propyl.
• C 2-6 alkynyl groups for R 5 and R 6 are ethynyl, 2-propynyl and 3-butynyl.
• hydroxy-C 1-6 alkyl groups for R 5 and R 6 are 3-hydroxypropyl, 4-hydroxybutyl and in particular 5-hydroxypentyl.
• C 1-6 alkoxy-C 1-6 alkyl groups for R 5 and R 6 are ethoxyethyl, ethoxymethyl and in particular methoxyethyl.
• substituted phenyl groups and the substituted phenyl moiety of the phenyl(C 1-6 ) alkyl groups for R 5 and R 6 are 3-methylphenyl, 3-methoxyphenyl, 3,4-dimethoxyphenyl and 3-chlorophenyl.
• optionally substituted furanyl-, thienyl- and pyridyl(C 1-6 alkyl) groups for R 5 and R 6 are optionally substituted 2-furanyl-, 2-thienyl-, 2-pyridyl-, 3-pyridyl-, or 4-pyridyl-(C 1-6 alkyl) groups, and particularly 3-pyridyl-, 6-methyl-3-pyridyl- and 6-methoxy-3-pyridyl-(C 1-6 alkyl).
• R 5 and R 6 are the same, preferably they are hydrogen, methyl, ethyl or n-propyl. Otherwise R 5 is preferably hydrogen and R 6 is as previously defined.
• Examples of C 4-6 alkylene groups for R 5 and R 6 when taken together are butane-1,4-diyl and pentane-1,5-diyl.
• R 5 and R 6 taken with the nitrogen atom to which they are attached can represent a piperidinyl or especially a pyrrolidinyl group.
• substituted phenyl groups for R 5 , R 6 and R 7 are 3-methylphenyl, 3-methoxyphenyl, 3,4-dimethoxyphenyl and 3chlorophenyl.
• optionally substituted furanyl, thienyl and pyridyl groups for R 5 and R 6 are optionally substituted 2-furanyl, 2-thienyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl groups, and particularly 3-pyridyl, 6-methyl-3-pyridyl and 6-methoxy-3-pyridyl.
• C 1-6 alkyl groups for R 8 are methyl, ethyl and n-propyl.
• R 7 is phenyl, 3pyridyl or 4-pyridyl and R 8 is hydrogen.
• Examples of pharmaceutically acceptable acid addition salts of compounds of formula (1) are those formed with hydrochloric, hydrobromic, sulphuric, phosphoric, acetic, citric, maleic, lactic, ascorbic and methanesulphonic acids.
• Compounds of formula (3) can be prepared by reacting a compound of formula (4): ##STR4## where R 1 to R 3 are as defined with reference to formula (1) and L is a leaving group displaceable with amine (for example C 1-6 alkylthio, C 1-6 alkoxy or phenoxy) with a hydrazine of formula (5): ##STR5## where R 4 is as defined with reference to formula (1).
• This reaction can be carried out in the presence of a solvent for example an aromatic hydrocarbon, in particular toluene; a C 1-6 alkanol in particular ethanol or iso-propanol; water; diethyl ether or dimethylformamide.
• a solvent for example an aromatic hydrocarbon, in particular toluene; a C 1-6 alkanol in particular ethanol or iso-propanol; water; diethyl ether or dimethylformamide.
• the reaction can be carried out at from room temperature to the reflux temperature of the solvent.
• the compound (3) forms and cyclises in situ to form the corresponding compound of formula (1).
• the compounds of formula (3) can also be prepared by reacting a compound of formula (6): ##STR6## with a compound of formula (7): ##STR7## or a derivative thereof where the NH 2 group is protected, L is a leaving group as defined with reference to formula (4) and R 4 is as defined with reference to formula (1) and thereafter removing any protecting group.
• the reaction can be carried out optionally in the presence of a solvent for example an aromatic hydrocarbon, particularly toluene; a C 1-6 alkanol particularly methanol, ethanol or iso-propanol; acetonitrile or water.
• a solvent for example an aromatic hydrocarbon, particularly toluene; a C 1-6 alkanol particularly methanol, ethanol or iso-propanol; acetonitrile or water.
• the reaction can be carried out at moderate temperatures for example from room temperature to the reflux temperature of any solvent present.
• the compound (3) forms and cyclises in situ to form the corresponding compound of formula (1).
• One protecting group which can be used in this process is the benzylidene group. This can be removed with aqueous hydrochloric acid or by heating with an amine.
• Compounds of formula (7) can be prepared by reacting a compound of formula (8): ##STR8## where L is as previously defined with the hydrazine of formula (5). This reaction is preferably carried out in a solvent for example an aromatic hydrocarbon (in particular toluene), a C 1-6 alkanol (in particular methanol or ethanol), diethyl ether or acetonitrile.
• a solvent for example an aromatic hydrocarbon (in particular toluene), a C 1-6 alkanol (in particular methanol or ethanol), diethyl ether or acetonitrile.
• R 5 and R 6 do not represent a group of formula (2) can be prepared by cyclizing a compound of formula (9): ##STR9## where R 1 to R 6 are as defined with reference to formula (1) except R 5 and R 6 are not a group of formula (2); E 1 is NH and E 2 is sulphur, oxygen or NH or E 1 is sulphur or oxygen and E 2 is NH.
• the reaction is preferably carried out by heating the compound of formula (9) in a polar organic solvent for example acetonitrile or dimethylformamide.
• a polar organic solvent for example acetonitrile or dimethylformamide.
• This reaction can be carried out in the presence of a solvent for example dimethylformamide.
• Compounds of formula (10) can be prepared by reacting a compound of formula (12): ##STR12## where R 1 to R 3 are as defined with reference to formula (1) with a C 1-6 alkylhalide or di-C 1-6 alkylsulphate in the presence of an acid.
• Compounds of formula (9) where E 1 is sulphur or oxygen, and R 5 and R 6 are hydrogen or C 1-6 alkyl can be prepared by reacting a compound of formula (13): ##STR13## where R 1 to R 3 are as defined with reference to formula (1) and E 1 is sulphur or oxygen with a compound of formula (11).
• the reaction can be carried out in the presence of a polar organic solvent for example a C 1-6 alkanol (particularly ethanol) or acetonitrile at from room temperature to the reflux temperature of the solvent.
• Compounds of formula (1) can be prepared by reacting a compound of formula (16): ##STR16## where R 1 to R 3 are as defined with reference to formula (1) and A is a group displaceable with amine, with a compound of formula (17): ##STR17## where R 4 to R 6 are as defined with reference to formula (1).
• Examples of groups displaceable with amine for A are tosyloxy and mesyloxy.
• the reaction between the aldehyde R 7 - or R 8 HCO or the ketone R 7 R 8 CO can be carried out in an organic solvent, particularly an aromatic hydrocarbon (especially benzene) or a C 1-6 alkanol (especially methanol or ethanol).
• the reaction is preferably carried out at a moderate temperature in particular at the reflux temperature of the solvent.
• reaction with formic acid and formaldehyde is an example of the Eschweiler-Clarke reaction and can be carried out under conditions which are standard for such reactions.
• Compounds of formula (1) can also be prepared by reacting a compound of formula (18): ##STR19## where R 1 to R 4 are as defined with reference to formula (1) with an amine of formula 19: ##STR20## where R 5 and R 6 are as defined with reference to formula (1).
• This reaction can be carried out in a polar organic solvent for example acetonitrile and in the presence of base for example potassium carbonate.
• a polar organic solvent for example acetonitrile
• base for example potassium carbonate
• Compounds of formula (18) can be prepared by reacting a compound of formula (1) where NR 5 R 6 is amino with sodium nitrite with a mineral acid, particularly hydrochloric acid and reacting the diazonium salt with cuprous chloride.
• the compounds of formula (20), (21), and (22) can be prepared by reacting a compound of formula (24) or (25) ##STR23## with 3-aminopropanol or 3-hydroxypropionitrile under basic conditions.
• the compounds of formula (23) can be prepared by successively reacting a compound of formula (25) with thionyl chloride and an amine R 1 R 2 NH.
• Compounds of formula (26) can in turn be prepared by reacting compounds of formula (23) or (24) with 1,3-propanediol in the presence of base.
• Acid addition salts of compounds of formula (1) can be formed from the corresponding bases by standard procedures for example by reacting the base with an acid in a C 1-6 alkanol or by the use of an ion-exchange resin. Salts of compounds of formula (1) can be interconverted using an ion-exchange resin.
• the activity of the compounds of formula (1) as histamine H 2 -antagonists can be demonstrated by their ability to inhibit histamine-stimulated secretion of gastric acid from the lumen-perfused stomachs of rats anaesthetised with urethane, and to reverse histamine-induced inhibition of contractions of the isolated rat uterus. These are actions of histamine which, according to Ash and Schild, Brit. J. Pharmac. Chemother. 27 247 (1966), are not mediated by histamine H 1 -receptors.
• histamine H 2 -antagonist activity of the compounds can also be demonstrated by the inhibition of histamine-stimulated acid secretion in the Heidenhain Pouch Dog, the inhibition of histamine-induced tachycardia in the isolated guinea pig right atrium and the inhibition of histamine-induced vasodilatation in the anaesthetised cat.
• Inhibition of histamine-stimulated secretion of gastric acid can be measured by using a lumen-perfused stomachs of rats anesthetised with urethane using the following modification of the method of Ghosh and Schild, Brit. J. Pharmac. Chemother. 13 54 (1958):
• mice Female Sprague-Dawley rats (160-200 g) are starved overnight and anaesthetised with urethane given intraperitoneally in one dose (200 mg).
• the trachea and jugular veins are both cannulated and a mid-line incision is made in the abdomen exposing the stomach which is cleared from connective tissue.
• a small incision is made in the rumen of the stomach and the stomach is washed with 5% w/v glucose solution.
• the oesophagus is partially cleared of connective tissue and cannulated with polythene tubing and the oesophagus and vagi are then cut above the cannula.
• An incision is made in the antrum and a cannula is passed into the stomach via the ruminal incision and through into the antrum so that the head of the cannula lies in the body of the stomach.
• a funnel-shaped cannula is inserted in the ruminal incision and tied into position so that the line between the rumen and the body coincides with the edge of the funnel.
• the antral cannula is tied into place to reduce the possibility that antrally released gastrin will effect gastric acid secretion.
• Two stab wounds are made in the abdominal wall, and the stomach cannulae passed through.
• the stomach is perfused through the oesophageal and stomach cannulae with 5.4% w/v glucose solution at 37° at 1-2 ml min -1 .
• the effluent is passed over a micro-flow pH electrode and recorded by a pH meter fed to an anti-log unit and flat-bed recorder.
• the basal output of acid secretion from the stomach is monitored by measurement of the pH of the perfusion effluent.
• a sub-maximal dose of histamine is continuously infused into the jugular vein and produces a stable plateau of acid secretion and the pH of the perfusion effluent is determined when this condition is obtained.
• ED 50 values for inhibiting sub-maximal acid secretion by 50% are determined by administering one dose of test compound to one rat and repeating this in at least four rats for each of three or more dose levels. The results obtained are then used to calculate the ED 50 value by the standard method of least squares.
• Heidenhain pouch dogs can be prepared and used as described in European Specification 15138.
• a spontaneously beating isolated portion of the guinea pig right atrium is secured under tension (300 mg) between an anchorage and a transducer in a 15 ml tissue bath and immersed in McEwens solution with constant aeration at a temperature of 37° C.
• the output from the transducer is amplified.
• Output is in turn fed to a flat bed recorder.
• Measured amounts of histamine are added to the tissue bath so that the histamine concentration increases step-wise until the rate of beating reaches a maximum.
• the tissue bath is washed out and filled with fresh McEwens solution containing compound under test. The solution is left in contact with the tissue for 60 min.
• DR dose ratio
• the products of the Examples have ED 50 values in the lumen-perfused rat test of less than 2.0 micromol kg -1 i.v. and pA 2 values in the guinea pig atrium test of more than 6.0.
• the ED 50 value for the compound of Example 3 is 0.14 micromol kg -1 and the pA 2 value is 7.38.
• the invention further provides pharmaceutical compositions comprising a compound of formula (1) above or a pharmaceutically acceptable acid addition salt thereof together with a pharmaceutically acceptable carrier.
• Compounds of formula (1) and their pharmaceutically acceptable acid addition salts may be administered orally, parenterally, cutaneously or rectally.
• a syrup formulation will generally consist of a suspension or solution of the compound or salt in a suitable liquid carrier for example, ethanol, glycerine or water with a flavouring or colouring agent.
• a suitable liquid carrier for example, ethanol, glycerine or water with a flavouring or colouring agent.
• any suitable pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.
• Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous carrier or parenterally acceptable oil.
• compositions for administration to the skin include lotions and creams in which the compound of formula (1) or salt thereof is contained in a liquid vehicle.
• a typical suppository formulation comprises a compound of formula (1) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as gelatin or cocoa butter or other low melting vegetable waxes or fats.
• composition is in unit dose form such as a tablet or capsule.
• Each dosage unit for oral administration contains preferably from 15 to 250 mg (and for parenteral administration contains preferably from 1.5 to 25 mg) of a compound of formula (1) or a pharmaceutically acceptable salt thereof calculated as the free base.
• the invention also provides a method of blocking histamine H 2 receptors which comprises administering to an animal an effective amount to block said receptors of a compound of formula (1) or a pharmaceutically acceptable acid-addition salt thereof.
• the daily dosage regimen for an adult patient is an oral dose of between 15 mg and 1500 mg and preferably between 20 mg and 250 mg or an intravenous, subcutaneous, or intramuscular dose of between 1.5 mg and 150 mg, and preferably between 5 mg and 20 mg of compound of formula (1) or pharmaceutically acceptable salt thereof calculated as the free base, the composition being administered 1 to 6 times per day.
• compositions of the invention will normally be administered to man for the treatment of peptic ulcers and other conditions caused or exacerbated by gastric acidity in the same general manner as that employed for known histamine H 2 -antagonists, due allowance being made in terms of dose levels for the potency of the compounds of the present invention relative to known histamine H 2 -antagonists.
• reaction mixture was concentrated to give a yellow oil which was triturated first with n-hexane then with ether to give a cream coloured solid which was recrystallised from toluene to give N 5 -3-(4-[1-piperidinomethyl]-pyridyl-2-oxy)propyl-1H-1,2,4-triazole-3,5-diamine (0.7 g) m.p. 139°-140° C. This was converted to the dioxalate with oxalic acid in ethanol m.p. 158°-159° C.
• N-cyano-S-methyl-N 1 -(3-[4-(1-piperidinomethyl)-pyridyl-2-oxy]propyl)isothiourea (1.5 g) and methyl hydrazine (1.5 ml) were stirred in dimethylformamide (15 ml) at room temperature for 48 hours.
• the reaction mixture was concentrated to give 1-methyl-N 5 -3-(4-[1-piperidinomethyl]-pyridyl-2-oxy)propyl-1H-1,2,4-triazole-3,5-diamine as a yellow oil which was washed with petroleum ether and isolated as the dioxalate.
• N-Cyano-1-methyl-2-(phenylmethylene)hydrazinecarboximidothioic acid methyl ester (26 g) was added to a solution of 3-(4-[1-piperidinomethyl]-pyridyl-2-oxy)propylamine (28 g) in ethanol (280 ml) and the mixture was stirred at room temperature for 48 hours. The mixture was then diluted with aqueous hydrochloric acid (2M; 225 ml) and the diluted mixture was allowed to stand for 3.5 hours.
• the aqueous mixture was extracted with ether, the ether extracts were washed with water and the ether extracts were discarded. The aqueous layer and water washings were combined.
• the combined aqueous solution was made alkaline to pH8 with sodium hydroxide (2M).
• the alkaline solution was extracted with chloroform, the chloroform extracts were dried (Na 2 SO 4 ) and evaporated to give 1-methyl-N5-3-(4-[1-piperidinomethyl]-pyridyl-2-oxy)propyl-1H-1,2,4-triazole-3,5-diamine as a brown oil.
• the amine was purified by converting it into the dioxalate, i.e.
• the dioxalate salt (37.0 g) was dissolved in water (200 ml) and made alkaline to pH12 with sodium hydroxide solution (10 ml) and the alkaline solution extracted with chloroform. The chloroform extract was dried (Na 2 SO 4 ). Crystallisation of the oil from acetonitrile/ether gave 1-methyl-N5-3-(4-[1-piperidinomethyl]-pyridyl-2-oxy)propyl-1H-1,2,4-triazole-3,5-diamine (20.5 g) m.p. 113°-114° C.
• a pharmaceutical composition for oral administration is prepared containing
• ingredients A substituted lactose or microcrystalline cellose for dibasic calcium phosphate dihydrate if desired
• a concentrated solution of polyvinylpyrrolidone and granulating, drying and screening the dried granules
• adding the ingredients B to the dried granules and compressing the mixture into tablets containing 100 mg, 150 mg or 200 mg of the free base.
• a pharmaceutical composition for injectable administration is prepared by converting 1-methyl-N 5 -3-(4-[1-piperidinomethyl]-2-oxy)propyl-1H-1,2,4-triazole-3,5-diamine into the dioxalate salt form and dissolving this in sterile pyrogen-free water to give a 1 to 5% w/w solution.
• the solution is clarified by filtration and filled into vials which are sealed and sterilised.
• a suitable vial contains 2 ml of the solution.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Pyridine Compounds (AREA)

Applications Claiming Priority (4)

Publications (1)

Family

ID=26282275

Family Applications (3)

Family Applications After (2)

Country Status (17)

Cited By (1)

Families Citing this family (8)

Citations (3)

Family Cites Families (8)

• 1983
  • 1983-03-04 EP EP83301160A patent/EP0089153B1/en not_active Expired
  • 1983-03-04 EP EP83301159A patent/EP0089765A3/en not_active Withdrawn
  • 1983-03-04 DE DE8383301160T patent/DE3366369D1/de not_active Expired
  • 1983-03-09 US US06/473,519 patent/US4551466A/en not_active Expired - Fee Related
  • 1983-03-09 US US06/473,520 patent/US4574126A/en not_active Expired - Fee Related
  • 1983-03-15 RO RO110331A patent/RO85384B/ro unknown
  • 1983-03-15 IL IL68130A patent/IL68130A0/xx unknown
  • 1983-03-15 JO JO19831244A patent/JO1244B1/en active
  • 1983-03-15 GR GR70799A patent/GR77155B/el unknown
  • 1983-03-15 PT PT76395A patent/PT76395B/pt unknown
  • 1983-03-16 CA CA000423753A patent/CA1192191A/en not_active Expired
  • 1983-03-16 GR GR70821A patent/GR77162B/el unknown
  • 1983-03-16 PL PL24105283A patent/PL241052A1/xx unknown
  • 1983-03-16 NO NO830932A patent/NO830932L/no unknown
  • 1983-03-17 AU AU12542/83A patent/AU1254283A/en not_active Abandoned
  • 1983-03-17 AU AU12541/83A patent/AU1254183A/en not_active Abandoned
  • 1983-03-17 FI FI830891A patent/FI830891L/fi not_active Application Discontinuation
  • 1983-03-17 DK DK123083A patent/DK123083A/da not_active Application Discontinuation
  • 1983-03-17 DD DD83248919A patent/DD206994A5/de unknown
  • 1983-03-17 ZW ZW68/83A patent/ZW6883A1/xx unknown
  • 1983-03-17 ES ES520709A patent/ES520709A0/es active Granted
  • 1983-03-17 DK DK123183A patent/DK123183A/da not_active Application Discontinuation
• 1985
  • 1985-10-31 US US06/793,510 patent/US4758576A/en not_active Expired - Fee Related

Patent Citations (3)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events